Solara Active Pharma Sciences Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/m3f4p9xdo5hbi04yl7glrhc8.pdf

Key Takeaways


The Mangalore Shutdown: What Happened and What It Cost

Sandeep Rao: "To give you a perspective; given the Mangalore operational shutdown, we lost almost INR30 crores to INR35 crores in top line and around INR18 crores to INR20 crores at a gross margin level."

P&L Walk: The Quarter in Numbers

Sarat Kumar: "We are confident of maintaining a healthy gross margin of more than 51% - 52%, that kind of a range. But depending on individual product mix for that particular certain quarter, we can see a range between 51% to 54% - 55% kind of a number."

Regulatory Milestones: The FDA Overhang Lifts

Sandeep Rao: "I acknowledge the disappointment because I thought in Q1 we were already on a growth curve and I hear you loud and clear about these setbacks that Solara keeps reporting. But I'd like to see the bright side of it also that in 2 quarters, we've cleared Ambernath and in this quarter Mangalore successfully with the FDA."

Balance Sheet & Liquidity: Repair in Progress


Growth Strategy: Products, Markets, and a Turnaround to Prove

Sandeep Rao: "We want to have at least 3, 4 quarters of growth just to prove it to ourselves even more than proving it to you that we have a turnaround story here."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue and EBITDA growth10% increment on sales, roughly 15-20% EBITDA growth (on FY25 base)FY26 full year
Gross margin rangeMaintain 51%+, with range of 51% to 54-55% depending on product mixOngoing
Debt reductionReduce debt to ~INR446 crores (net debt-to-EBITDA of ~1.5x)By Q1 FY27
Debt transfer via demergerINR200 crores transferred to CRAMS and polymer businessOn demerger completion
Deferred sales recoveryService the INR35 crores of deferred Q2 salesOver Q3 and Q4 FY26
Liquidity resolutionResolve the current tight liquidity positionRoughly 2 quarters
Aspirational marginsAchieve aspirational margin levelsBy Q4 FY26
Vizag facility restartRestart operationsOnly once CRAMS partnerships are secured

Key Metrics

MetricQ2 FY26
Revenue₹314 cr, 2% decline QoQ
Gross margin51%, down 264 bps QoQ; absolute gross margin of ₹160 cr, down ~8% QoQ
EBITDA₹35.2 cr, ~39% decline QoQ
EBITDA margin11%
Operating costsUp ~₹8.9 cr QoQ, including ~₹4 cr one-time Mangalore upgrade cost
Revenue lost from Mangalore shutdown₹30–35 cr in top line, ₹18–20 cr at gross margin level
Regulated markets revenue share75% of overall sales
Gross debt reduction in H1 FY26~₹153 cr, ~20% reduction in opening debt; ₹113 cr from rights issue, ~₹40 cr from operations
Target gross debt by Q1 FY27~₹446 cr, with net debt-to-EBITDA of ~1.5x
U.S. DMF filings90–95 total, 35–40 active products
FY26 outlook (from Q1)10% revenue growth, 15–20% EBITDA growth over FY25
Cost of debt~13%
H1 FY26 capex~₹29 cr
Ibuprofen plain gross margin~20–22%
Ibuprofen derivatives gross margin~8–10%